• Plk1 Regulation of p31comet in Mitotic Checkpoint Disassembl

  2026-08-04

  This study elucidates how Polo-like kinase 1 (Plk1) directly regulates the Mad2-binding protein p31comet through phosphorylation, modulating the disassembly of mitotic checkpoint complexes (MCC) and thus controlling the fidelity of chromosome segregation. The findings clarify a crucial inhibitory mechanism that prevents premature checkpoint inactivation during mitosis, with implications for targeting mitotic regulators in cancer research.

• Nanomedicine Restores Stromal Balance in Pancreatic Cancer M

  2026-08-04

  Fu et al. introduce an acid-responsive, multi-stage nanomedicine designed to remodel the dense stroma of pancreatic ductal adenocarcinoma (PDAC), significantly enhancing gemcitabine delivery and promoting tumor regression in vivo. This strategy demonstrates the value of stromal homeostasis restoration—rather than ablation—in overcoming chemoresistance and improving therapeutic outcomes.

• Sunitinib in RCC: Overcoming Resistance and Advancing Assays

  2026-08-03

  Explore how Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, is redefining renal cell carcinoma research through novel resistance-overcoming strategies and advanced protocol insights. Discover unique, evidence-backed assay guidance.

• Phosbind Acrylamide: Advancing Phosphate-Binding Reagent Sci

  2026-08-03

  Discover how Phosbind Acrylamide revolutionizes protein phosphorylation analysis with superior phosphate-binding capability, enabling antibody-free SDS-PAGE detection. This article uniquely explores mechanistic insights and practical assay decisions, setting it apart from existing content.

• Repurposed Vitamins as SARS-CoV-2 3CLpro and Spike RBD Inhib

  2026-08-02

  Eskandari (2022) identifies several natural vitamin derivatives as potential inhibitors of the SARS-CoV-2 main protease and spike receptor-binding domain using molecular docking and dynamics. The study offers a mechanistic basis for repurposing safe, accessible compounds in antiviral therapeutics research, highlighting new targets for COVID-19 intervention strategies.

• TBXA2R-ERM Signaling Drives Motility and Metastasis in TNBC

  2026-08-01

  The reference study uncovers TBXA2R as a direct activator of ERM proteins, elucidating a new GPCR-driven signaling axis that promotes cell motility, invasion, and metastatic colonization in triple-negative breast cancer (TNBC) cells. These insights clarify previously unknown mechanisms of cytoskeletal remodeling in cancer metastasis and highlight potential avenues for therapeutic targeting.

• ARCA Cy5 EGFP mRNA (5-moUTP): Precision Tools for Dissecting

  2026-07-31

  Explore how ARCA Cy5 EGFP mRNA (5-moUTP) enables rigorous, quantitative dissection of mRNA delivery and translation barriers in mammalian cells. This article uniquely applies advanced assay design and practical protocol insights to address the persistent challenges in efficient mRNA-based research and therapy.

• PP 2 (AG 1879): Validating Src Kinase Inhibition in Cell Ass

  2026-07-31

  This article provides scenario-driven guidance for leveraging PP 2 (AG 1879) (SKU A8216) as a selective Src family kinase inhibitor in cell viability, proliferation, and cytotoxicity workflows. Through evidence-based Q&A, it addresses common pitfalls, detailed optimization, and vendor reliability, supporting researchers seeking reproducible, quantitative outcomes.

• Z-VAD-FMK (Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylke

  2026-07-30

  This article addresses real-world laboratory challenges in apoptosis research, focusing on the robust, reproducible performance of Z-VAD-FMK (Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone) (SKU A1902). By integrating scenario-driven Q&A, protocol guidance, and evidence-backed comparisons, researchers can optimize data integrity and workflow efficiency with this pan-caspase inhibitor.

• AR and ARv7 in TNBC: Prognostic Impact and EPI-001 Mechanism

  2026-07-30

  This study establishes that androgen receptor (AR) and its splice variant ARv7 are markers of poor prognosis and metastasis risk in triple-negative breast cancer (TNBC). It demonstrates that targeting AR/ARv7—particularly with the N-terminal domain inhibitor EPI-001—modulates metastatic and EMT pathways, highlighting new opportunities for therapeutic research.

• Tariquidar (XR9576): Benchmarks for ABC Transporter Inhibiti

  2026-07-29

  Tariquidar (XR9576) is a potent, selective inhibitor of P-glycoprotein (P-gp), widely used in drug resistance research to block transporter-mediated efflux. Its nanomolar potency and specificity underpin robust protocols for dissecting ABC transporter function and chemoresistance. This article details Tariquidar’s mechanisms, validated workflows, and common pitfalls for high-fidelity cancer research.

• Palonosetron Hydrochloride: Innovations in Preventing CINV

  2026-07-29

  Ruhlmann and Herrstedt’s review delineates the mechanistic and clinical advantages of palonosetron hydrochloride, a next-generation 5-HT3 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV). Their synthesis highlights palonosetron’s unique pharmacological properties, including its long half-life and allosteric receptor binding, which translate into superior efficacy in both acute and delayed CINV phases.

• Nintedanib (BIBF 1120): Optimizing Antiangiogenic Research W

  2026-07-28

  Nintedanib (BIBF 1120) stands out as a robust triple angiokinase inhibitor for translational oncology and fibrosis models, enabling reproducible pathway inhibition across VEGFR, PDGFR, and FGFR targets. This guide details evidence-backed protocols, practical troubleshooting, and cutting-edge applications—especially in ATRX-deficient tumor systems—to maximize research impact.

• Carboplatin in Preclinical Oncology: Mechanisms, Models, and

  2026-07-28

  Explore Carboplatin as a platinum-based DNA synthesis inhibitor with a focus on mechanistic insight and advanced assay optimization for cancer research. This article offers a unique, evidence-based perspective on experimental design and translational impact, grounded in recent systematic reviews.

• Dual-Reporter mRNA Advances: Mechanistic Insights and Strate

  2026-07-27

  This thought-leadership article explores how dual-reporter, 5-moUTP-modified mRNA tools like EZ Cap™ Cy5 Firefly Luciferase mRNA transform translational research. It blends mechanistic insight—focusing on cap structure, nucleotide modification, and real-time detection—with practical guidance for optimizing mRNA delivery, tracking, and translation efficiency. Evidence from recent microfluidic LNP manufacturing studies and benchmark internal assets is integrated to elevate the discussion beyond standard product pages, providing strategic direction for researchers bridging preclinical and clinical workflows.

451 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page